Application of pterostilbene in inhibiting vascular endothelial apoptosis

A technology of vascular endothelium and pterostilbene, applied in the field of application of pterostilbene in the preparation of drugs for inhibiting apoptosis of vascular endothelial cells

Active Publication Date: 2013-07-03
HENAN UNIVERSITY OF TECHNOLOGY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current research reports on the biological activity of pterostilbene are mostly limited to anti-inflammation and anti-tumor effects, and its role in inhibiting apoptosis of vascular endothelial cells and related pharmacological research and application have been retrieved by authoritative organizations. Not yet reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pterostilbene in inhibiting vascular endothelial apoptosis
  • Application of pterostilbene in inhibiting vascular endothelial apoptosis
  • Application of pterostilbene in inhibiting vascular endothelial apoptosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1: Application of Pterostilbene in the Preparation of Drugs for Inhibiting Vascular Endothelial Cell Apoptosis

[0079] Preparation of vascular endothelial cells: Culture vascular endothelial cells by conventional methods, and select vascular endothelial cells in good growth state and in logarithmic growth phase for future use.

[0080] The cultured cells were divided into solvent control group, pterostilbene treatment group, oxidized low-density lipoprotein treatment group, pterostilbene and oxidized low-density lipoprotein co-treatment group.

[0081] The solvent control group was incubated with 1 μM DMSO for 24 or 48 hours; the pterostilbene treatment group was incubated with 1 μM pterostilbene alone for 24 or 48 hours; the oxidized low-density lipoprotein group was incubated with 200 μg / mL oxidized low-density lipoprotein for 24 hours. or 48 hours; pterostilbene and oxidized low-density lipoprotein co-treatment group was pretreated with 1 μM pterostilbene fo...

Embodiment 2

[0084] Example 2: Application of Pterostilbene in the Preparation of Drugs for Inhibiting Vascular Endothelial Cell Apoptosis

[0085] Preparation of vascular endothelial cells: Culture vascular endothelial cells by conventional methods, and select vascular endothelial cells in good growth state and in logarithmic growth phase for future use.

[0086] The cultured cells were divided into solvent control group, pterostilbene treatment group, oxidized low-density lipoprotein treatment group, pterostilbene and oxidized low-density lipoprotein co-treatment group.

[0087] The solvent control group was incubated with 1 μM DMSO for 24 hours; the pterostilbene treatment group was incubated with 1 μM pterostilbene alone for 24 hours; the oxidized low-density lipoprotein group was incubated with 200 μg / mL oxidized low-density lipoprotein for 24 hours; The stilbene and oxidized low-density lipoprotein co-treatment group was pretreated with 1 μM pterostilbene for 2 hours, and then incuba...

Embodiment 3

[0090] Example 3: Application of Pterostilbene in the Preparation of Drugs for Inhibiting Vascular Endothelial Cell Apoptosis

[0091] Preparation of vascular endothelial cells: Culture vascular endothelial cells by conventional methods, and select vascular endothelial cells in good growth state and in logarithmic growth phase for future use.

[0092] Vascular endothelial cells were seeded in 96-well culture plates. In the blank group, no cells were added to each well, and 100 μL of cell culture medium was added for culture. Prepare pterostilbene at concentrations of 0.1 μM, 0.5 μM, 1 μM, and 5 μM, add them to the culture medium of vascular endothelial cells, pretreat the cells for 2 hours, and then add 200 μg / mL oxidized low-density lipoprotein to each well and incubate for 24 or 48 hours . 4 hours before the end of the drug treatment, 20 μL of MTT was directly added to each well of each group, and the culture was continued for 4 hours. Discard the culture medium in each w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of pterostilbene in inhibiting vascular endothelial apoptosis. The effective concentration of the pterostilbene in application of inhibiting vascular endothelial apoptosis is between 0.5 and 5 mu M. The function of the pterostilbene in inhibiting vascular endothelial apoptosis is sufficiently proved in a cell morphological alteration experiment observed by an inverted phase contrast microscope, a nucleus condensation and karyorrhexis situation experiment observed by a laser scanning confocal microscope, a nucleus heterochromatin agglutination situation experiment observed by a Tunel fluorescence microscope, a dye marked apoptotic cell experiment, an activity experiment of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay detectedcell succinodehydrogenase, an affecting experiment of the pterostilbene to apoE- / - mice aortic vascular endothelial apoptosis detected by a frozen section immunofluorescence staining method, a JC-1 dyeing detected mitochondrial membrane potential change experiment and a Westernblot detected apoptosis related protein expression experiment. The pterostilbene has remarkable effect in inhibiting vascular endothelial apoptosis, so that an attractive prospect is provided to the development of preparing a medicament for inhibiting vascular endothelial apoptosis and a novel cardiovascular medicament.

Description

technical field [0001] The invention relates to an application of pterostilbene, in particular to an application of pterostilbene in preparing a medicine for inhibiting apoptosis of vascular endothelial cells. Background technique [0002] Pterostilbene structural formula is: [0003] [0004] The molecular formula of pterostilbene is C 16 h 16 o 3 , the molecular weight is 256.3, the properties are white or off-white powder crystals, soluble in ethanol, ether, benzene and acetone, and can dissolve various organic and inorganic compounds. [0005] Pterostilbene is a resveratrol derivative naturally present in blueberries and grapes, which has various pharmacological activities, including anti-tumor, anti-inflammatory, anti-oxidative and anti-diabetic. Now, resveratrol is a research focus because of its pharmacological and medicinal properties and its potential economic value. The structural similarity between pterostilbene and resveratrol makes them have similar anti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/09A61P9/00
Inventor 张璐陈良珂崔柳青周广舟张宗武景红娟
Owner HENAN UNIVERSITY OF TECHNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap